skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Metabolic activation and antineoplastic-selective mechanism of action of two novel fluoropyrimidines

Thesis/Dissertation ·
OSTI ID:5514468

The coadministration of tetrahydrouridine (H/sub 4/Urd) diverted the metabolism of /sup 3/H-5-fluoro-2'-deoxycytidine (FdCyd) in human epidermoid laryngeal carcinoma (HEp-2) cells through the deoxycytidine kinase-deoxycytidylate deaminase (dCK-dCMPD) pathway to the formation of 5-fluorodeoxyuridylate (FdUMP) without the incorporation of 5-fluorouridylate (FUMP) into RNA or the formation of RNA-level antimetabolite pools. Antimetabolite pool sizes, as assayed by HPLC, following treatment of BD2F/sub 1/ mice bearing ascitic mammary adenocarcinoma-755 (ADC-755) or Lewis lung carcinoma (LLC) with /sup 3/H-FdCyd + H/sub 4/ Urd resulted in pool sizes indicative of a tumor-selective, dual pathway metabolism of FdCyd via both the cytidine deaminase-deoxythymidine kinase (CD-dTK) and dCK-dCMPD pathways. In contrast to the high levels of all RNA- and DNA-level antimetabolites derived from FdCyd found in tumor tissue, in normal tissues (bone marrow, intestine, liver and spleen) and in serum, FdCyd was metabolized to only a small extent, all antimetabolite pools were markedly lower. /sup 3/H-FdCyd + H/sub 4/Urd exposure resulted in selective incorporation of antimetabolites into tumor RNA and DNA. dCMPD and CD enzyme assays have confirmed that H/sub 4/Urd administration effectively inhibited the low CD activity in normal, but not the elevated levels found in tumor tissue.

Research Organization:
Miami Univ., FL (USA)
OSTI ID:
5514468
Resource Relation:
Other Information: Thesis (Ph. D.)
Country of Publication:
United States
Language:
English